Share on LinkedInShare on LinkedIn

ARTICLE · 07 JANUARY 2026

Hoffmann Test For Assessing Inventive Step Applied: Appeal Dismissed By Delhi High Court

In Amylin Pharmaceuticals LLC & Anr. vs Assistant Controller of Patents (C.A.(COMM.IPD-PAT) 76/2022), the Delhi High Court upheld the refusal of a patent application for a sustained-release exenatide injection for diabetes.

IndiaIntellectual Property

In Amylin Pharmaceuticals LLC & Anr. vs Assistant Controller of Patents (C.A.(COMM.IPD-PAT) 76/2022), the Delhi High Court upheld the refusal of a patent application for a sustained-release exenatide injection for diabetes. The Court in this appeal case examined whether the claimed invention exhibits an inventive step under Section 2(1)(ja) of the Patents Act, 1970, in the light of Documents D1 to D4 cited by the Controller for rejection of the patent application 1498/DELNP/2011 titled "Sustained release formulations using non-aqueous carriers". To carry out the inventive step analysis, the Court used the procedure for assessing the inventive step as laid down in the judgment of the Court in Hoffmann-La Roche Ltd. vs Cipla Ltd. [(2016) 65 PTC 1 (Del)].

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from